Sales 3rd quarter 2024

9-month sales: €398 million (+1.8% at constant exchange rates and +1.6% on a reported basis)
9-month sales of essential products: €241million (+3.9% at constant exchange rates and on a reported basis)

At the end of September 2024, Vetoquinol sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates. Over the same period, the laboratory recorded net negative currency impacts of €-1 million, linked to the Americas and Asia Pacific/Rest of World territories, partially offset by positive currency impacts of +1.4M€ on the Europe territory.

Sales of Essential products totaled €241 million, up +3.9% on a reported basis and at constant exchange rates. Essential products accounted for 61% of the laboratory's sales at September 30, 2024, compared with 59% for the same period in 2023.

At constant exchange rates, the strategic territories of Europe and Asia-Pacific/Rest of World grew by +3.6% and +12.3% respectively; the United States remained down -11.5% due to the situation described at the time of the presentation of Half-Year Results 2024, namely a drop in inventories with American wholesalers and the temporary unavailability of a range of products. Excluding the United States, the Americas territory grew by +7.6%.

Sales of products for companion animals (€281 million) rose by 1.6% at constant exchange rates, and accounted for 70.4% of the laboratory's total sales. Sales to farm animals came to €117 million, up +2.0% at constant exchange rates.

Vetoquinol recorded sales of €134 million in the 3rd quarter of FY 2024, stable (-0.5% at constant exchange rates.) Foreign exchange had a negative impact of €1 million (-1.0%), mainly in the Americas excluding the United States. 

The laboratory's cash position strengthened in the third quarter of 2024.

Sales for the first 9 months of 2024 have not been audited by the Statutory Auditors.

ANNEX

ALTERNATIVE PERFORMANCE INDICATORS
Vetoquinol Group management considers that these indicators, which are not defined by IFRS, provide additional information that is relevant for shareholders seeking to analyze underlying trends and Group performance and financial position. They are used by management for performance analysis.

Essentials products: The products referred to as “Essentials” comprise veterinary drugs and non-medical products sold by the Vetoquinol Group. They are existing or potential market-leading products designed to meet the daily requirements of vets in the companion animal or livestock sector. They are intended for sale worldwide and their scale effect improves their economic performance.

Constant exchange rates: Application of the previous period’s exchange rates to the current financial year, all other things remaining equal.

Like-for-like (LFL) growth: Year-on-year sales growth in terms of volume and/or price at constant consolidation scope and exchange rates.

Press release